Vanguard Group Inc. Boosts Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Vanguard Group Inc. increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,085,456 shares of the biotechnology company's stock after acquiring an additional 117,904 shares during the period. Vanguard Group Inc. owned approximately 9.51% of Sarepta Therapeutics worth $1,104,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares during the period. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after buying an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics during the fourth quarter worth about $36,000. Finally, Steward Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 194 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Remove Ads

Sarepta Therapeutics Trading Down 9.4 %

Sarepta Therapeutics stock traded down $6.59 during mid-day trading on Monday, hitting $63.82. The company's stock had a trading volume of 4,633,758 shares, compared to its average volume of 1,270,108. Sarepta Therapeutics, Inc. has a 1 year low of $62.53 and a 1 year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $6.19 billion, a PE ratio of 51.06 and a beta of 0.79. The stock's fifty day moving average is $102.66 and its two-hundred day moving average is $115.90.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SRPT shares. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Royal Bank of Canada cut shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price objective for the company from $161.00 to $87.00 in a report on Monday. Cantor Fitzgerald reissued an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Needham & Company LLC restated a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, HC Wainwright reiterated a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $164.05.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.